Enviado: 20/7/2005 20:52There is a tug of war for dollars on Wall Street this week. The tug of war is between technology and biotech. Technology won on Monday night. But Tuesday night belonged to biotech.
On the heel of Tuesday's news, the growth dollars are heading to biotech after Amgen (AMGN:Nasdaq - commentary - research) and Gilead (GILD:Nasdaq - commentary - research) reported great second-quarter numbers after the closing bell.
But Jim Cramer told his "Mad Money" viewers on CNBC that biotech will do especially well in the future -- especially if investors compare them with the Big Pharma stocks of today.
Investors also will be looking to put money to work in Genentech (DNA:NYSE - commentary - research), Celgene (CELG:Nasdaq - commentary - research) and Genzyme (GENZ:Nasdaq - commentary - research). In fact, Cramer said, he never wants to hear about Pfizer (PFE:NYSE - commentary - research) and Merck (MRK:NYSE - commentary - research) again.
"We want to be looking for stocks that will be in our kids' medicine cabinets," he said. Pfizer and Merck have the stuff that is in cabinets today, he said.
What's more, Cramer said that Big Pharma doesn't innovate anymore. They just repackage stuff so that they can squeeze out every last dime. The biotech companies are the future of pharmaceuticals, he said.
"Get into biotech now to make money off of lifesaving drugs," Cramer concluded.
Vm, não estou na ADN apenas porque nunca me debrucei sobre ela, é de facto um título com um comportamento estável dentro do sector.
Eu acredito no longo prazo do sector.
Em termos de curto prazo a euforia impera, vou aproveitar a corrente e só reduzo posição quando vir sinais de inversão.